Workflow
宁科生物(600165) - 2020 Q1 - 季度财报
NSWRCNSWRC(SH:600165)2020-04-24 16:00

Financial Performance - Operating revenue decreased by 57.76% to CNY 20,857,657.03 year-on-year[6] - Net profit attributable to shareholders was CNY 1,528,035.07, a significant recovery from a loss of CNY 5,362,273.69 in the same period last year[6] - The weighted average return on equity was 0.1697%, up from -0.6177% year-on-year[6] - Basic earnings per share increased to CNY 0.0022 from a loss of CNY 0.0078 in the same period last year[6] - Total revenue for Q1 2020 was ¥20,857,657.03, a decrease of 57.8% compared to ¥49,374,483.80 in Q1 2019[37] - Net profit for Q1 2020 was ¥1,214,241.21, a significant recovery from a net loss of ¥5,604,414.16 in Q1 2019[38] - The net profit for Q1 2020 was 6,012,921.32 million RMB, a significant improvement from a net loss of 667,326.77 million RMB in Q1 2019[43] - The total profit for Q1 2020 was 6,012,921.32 million RMB, compared to a loss of 667,326.77 million RMB in the same period last year[42] Cash Flow and Liquidity - The net cash flow from operating activities improved to -CNY 9,204,499.83, compared to -CNY 33,461,726.04 in the previous year[6] - The company's cash and cash equivalents increased by 121.08%, reaching ¥371,729,416.34 from ¥168,139,487.04 at the beginning of the year[14] - Cash flow from operating activities in Q1 2020 was -9,204,499.83 million RMB, an improvement from -33,461,726.04 million RMB in Q1 2019[46] - The net increase in cash and cash equivalents for Q1 2020 was 214,715,723.38 million RMB, compared to 3,016,571.72 million RMB in Q1 2019[47] - The ending balance of cash and cash equivalents for Q1 2020 was 345,435,465.30 million RMB, significantly higher than 25,142,586.27 million RMB at the end of Q1 2019[47] Assets and Liabilities - Total assets increased by 14.05% to CNY 2,563,451,777.96 compared to the end of the previous year[6] - The company's total assets amounted to CNY 2,563,451,777.96, an increase from CNY 2,247,718,828.91 at the end of 2019, reflecting a growth of approximately 14%[26] - Total liabilities increased to CNY 1,637,131,772.85 as of March 31, 2020, from CNY 1,322,613,065.01 at the end of 2019, marking an increase of around 24%[28] - The company's long-term borrowings increased significantly by 733.33%, from ¥30,000,000.00 to ¥250,000,000.00[14] - The company's short-term borrowings rose to CNY 510,800,000.00, compared to CNY 404,100,000.00 at the end of 2019, reflecting an increase of approximately 26%[27] Shareholder Information - The total number of shareholders reached 31,956 by the end of the reporting period[10] - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 200,000,000 shares, accounting for 29.20% of total shares[10] Government Support - The company received government subsidies totaling CNY 3,222,152.58, which contributed positively to the financial results[7] - The company received government subsidies, contributing to an increase in other income and investment income[13] Litigation - The company is involved in ongoing litigation regarding performance commitments and compensation, with claims amounting to ¥1.57 billion for the years 2017 and 2018[17] - The company has ongoing litigation regarding unfulfilled performance commitments from 2017 and 2018, with claims amounting to CNY 1.57 billion for each year, which are still pending resolution[22] Operating Costs and Expenses - Operating costs fell to ¥20,987,040.90, a decrease of 51.77% compared to ¥43,512,941.96 in the previous year[15] - The company's financial expenses decreased by 31.90%, from ¥8,503,458.92 to ¥5,790,537.23[15] - Research and development expenses for Q1 2020 were ¥220,952.96, an increase from ¥116,762.24 in Q1 2019[37] - The company reported a decrease in sales expenses and management expenses, contributing to improved profitability[42]